Brokerages expect IDEXX Laboratories, Inc. (NASDAQ:IDXX) to report $0.93 earnings per share for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for IDEXX Laboratories’ earnings, with the highest EPS estimate coming in at $0.99 and the lowest estimate coming in at $0.89. IDEXX Laboratories posted earnings per share of $0.65 in the same quarter last year, which indicates a positive year-over-year growth rate of 43.1%. The company is expected to issue its next earnings report on Friday, April 27th.
On average, analysts expect that IDEXX Laboratories will report full year earnings of $4.11 per share for the current fiscal year, with EPS estimates ranging from $4.04 to $4.21. For the next fiscal year, analysts forecast that the business will post earnings of $4.87 per share, with EPS estimates ranging from $4.75 to $5.03. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover IDEXX Laboratories.
IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Thursday, February 1st. The company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.73 by $0.04. The business had revenue of $506.00 million for the quarter, compared to the consensus estimate of $490.51 million. IDEXX Laboratories had a negative return on equity of 432.19% and a net margin of 13.36%. The company’s revenue was up 14.2% compared to the same quarter last year. During the same period last year, the business posted $0.58 EPS.
IDEXX Laboratories (IDXX) traded down $0.73 during mid-day trading on Friday, hitting $203.80. The stock had a trading volume of 210,024 shares, compared to its average volume of 585,860. The stock has a market cap of $17,780.00, a P/E ratio of 62.21, a P/E/G ratio of 2.51 and a beta of 0.58. IDEXX Laboratories has a 52-week low of $146.09 and a 52-week high of $206.49. The company has a current ratio of 0.97, a quick ratio of 0.80 and a debt-to-equity ratio of -11.26.
In other IDEXX Laboratories news, CEO Jonathan W. Ayers sold 18,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $165.15, for a total transaction of $2,972,700.00. Following the completion of the transaction, the chief executive officer now owns 1,077,112 shares in the company, valued at $177,885,046.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Brian P. Mckeon sold 6,602 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $181.36, for a total value of $1,197,338.72. Following the transaction, the vice president now owns 47,040 shares of the company’s stock, valued at approximately $8,531,174.40. The disclosure for this sale can be found here. Insiders have sold 91,736 shares of company stock valued at $16,193,502 in the last 90 days. Company insiders own 2.77% of the company’s stock.
Several large investors have recently made changes to their positions in IDXX. Cabot Wealth Management Inc. raised its holdings in shares of IDEXX Laboratories by 3.5% in the 4th quarter. Cabot Wealth Management Inc. now owns 9,050 shares of the company’s stock valued at $1,415,000 after purchasing an additional 309 shares in the last quarter. Norinchukin Bank The raised its position in IDEXX Laboratories by 6.2% during the third quarter. Norinchukin Bank The now owns 6,495 shares of the company’s stock valued at $1,010,000 after acquiring an additional 379 shares in the last quarter. Cubist Systematic Strategies LLC raised its position in IDEXX Laboratories by 5.3% during the third quarter. Cubist Systematic Strategies LLC now owns 7,662 shares of the company’s stock valued at $1,191,000 after acquiring an additional 384 shares in the last quarter. Catalyst Capital Advisors LLC raised its position in IDEXX Laboratories by 2.3% during the fourth quarter. Catalyst Capital Advisors LLC now owns 17,600 shares of the company’s stock valued at $2,752,000 after acquiring an additional 400 shares in the last quarter. Finally, Synovus Financial Corp raised its position in IDEXX Laboratories by 18.1% during the third quarter. Synovus Financial Corp now owns 2,655 shares of the company’s stock valued at $408,000 after acquiring an additional 406 shares in the last quarter. Institutional investors and hedge funds own 87.09% of the company’s stock.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.